Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 12/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 11/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 11/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 9/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 7/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Scriptaid SCHEMBL29383029 | 1.00 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL29382031 | 0.94 | ALDH1A1 (0.90) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL411511 | 0.94 | ALDH1A1 (0.90) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL5852563 | 0.91 | HDAC8 (0.83) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL10323380 | 0.88 | ALDH1A1 (0.79) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL14862921 | 0.87 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL30304758 | 0.87 | HDAC8 (1.00) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL19513510 | 0.87 | HDAC1 (0.76) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL20258450 | 0.85 | KDM4E (0.84) | HDAC8HDAC3HDAC1HDAC11HDAC6 | |
| SCHEMBL18373230 | 0.85 | ALDH1A1 (0.74) | HDAC8HDAC3HDAC1HDAC11HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4673532-A1 | THERAPY | Plasticell Limited (GB) | 2026-01-07 | — | — | EP | claimed |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | YALE UNIVERSITY (US) | 2025-12-16 | — | — | US | claimed |
| US-20250375441-A1 | ONCOLYTIC THERAPY WITH A DUAL HDAC3 AND HDAC8 TARGETING AGENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-12-11 | — | — | US | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| EP-2117536-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACYLATED AMINO ACIDS AND STRUCTURALLY RELATED COMPOUNDS | Beiersdorf AG (DE) | 2009-11-18 | — | — | EP | claimed |
| EP-2114442-A1 | HAT ACETYLATION PROMOTERS AND USES OF COMPOSITIONS THEREOF IN PROMOTING IMMUNOGENICITY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-11 | — | — | EP | claimed |
| WO-2008101692-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE | BEIERSDORF AG (DE) | 2008-08-28 | — | — | WO | claimed |
| WO-2008101693-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACYLATED AMINO ACIDS AND STRUCTURALLY RELATED COMPOUNDS | BEIERSDORF AG (DE) | 2008-08-28 | — | — | WO | claimed |
| WO-2008090534-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EXCESSIVE WEIGHT GAIN, REDUCTION OF INAPPROPRIATE EATING BEHAVIOURS AND INHIBITION OF BINGE EATING FOR THE TREATMENT OF OBESITY | BERAND LIMITED (IE) | 2008-07-31 | — | — | WO | claimed |
| WO-2008086610-A1 | HAT ACETYLATION PROMOTERS AND USES OF COMPOSITIONS THEREOF IN PROMOTING IMMUNOGENICITY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-07-24 | — | — | WO | claimed |
| WO-2008086612-A1 | HAT ACETYLATION PROMOTERS AND USES OF COMPOSITIONS THEREOF IN PROMOTING IMMUNOGENICITY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-07-24 | — | — | WO | claimed |
| WO-2007049262-A1 | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders | BERAND LIMITED (IE) | 2007-05-03 | — | — | WO | claimed |
| US-20060148684-A1 | Use of a histone deacetylase inhibitor for treating muscular dystrophies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2006-07-06 | — | — | US | claimed |
| US-20010031722-A1 | Methods and reagents for facilitating transcription | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | HBB, HBG1, HBZ | HDAC8 4661/4885HDAC3 4845/4885HDAC1 4862/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | HDAC8 19/4885HDAC3 97/4885HDAC1 71/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | HDAC8 555/4885HDAC3 2450/4885HDAC1 2024/4885 |
| US-20250375441-A1 | ONCOLYTIC THERAPY WITH A DUAL HDAC3 AND HDAC8 TARGETING AGENT | HDAC8, HDAC1, HDAC3 | HDAC8 1/4885HDAC3 3/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.